Several members of a series of N-(fluorenyl-9-methoxycarbonyl) amino acids were found to possess a broad spectrum of antinflammatory activity. The compounds were active against oxazolone dermatitis in mice and adjuvant arthritis in rats, models in which activated T lymphocytes are
Implicated. The compounds also inhibited T-lymphocyte activation in vitro, ased by using the mixed lymphocyte reaction. The compounds inhibited the reversed passive Arthus reaction in rats and arachidonic acid-induced dermatitis in mice, models in which leukocyte inf tion ls responsible for the inflammatory reaction. More complete evaluation was made of one compound, N-(fluorenyl-9-methoxycarbonyl)leucine (NPC 15199). On histologic emination after arachidonic acid adminstration, NPC 15199 was found to block recruitment of neutrophils into the inflammatory site. The compound was not a general myelotoxin. Prolonged treatment of animals did not alter bone-marrow progenitor number or the numbers of circulating white blood cells. Further, several white cell functions were not inhibited in vitro, including neutrophil respiratory burst and macrophage phagocytosis. NPC 15199 was effective in blocking antigen arthritis in rabbits and was effective in a therapeutic protocol, reversing oxazolone edema. These studies suggest that N-(fluorenyl-9-methoxycarbonyl) amino acids may be valuable therapeutic agents for inflammatory diseases.
Current therapy for chronic inflammatory diseases is unsatisfactory., Nonsteroidal antiinflammatory drugs (NSAIDs) reduce symptoms but do not prevent progression of disease and have serious side effects, including gastric ulceration. Glucocorticosteroids provide dramatic relief in some diseases but with systemic side effects, which often precludes chronic use at efficacious doses. Certain cytotoxic agents can provide substantial relief but elicit major toxicity (1) .
Bone marrow-derived leukocytes, in particular, neutrophils, are responsible for much of the damage in inflammatory reactions. In addition, T lymphocytes participate in maintenance of chronic inflammatory diseases, which can be transferred by injecting T lymphocytes from a diseased animal into a nondiseased animal (2) . Cytotoxic agents such as cyclophosphamide and methotrexate act in chronic inflammatory diseases by depleting neutrophils and T lymphocytes (1), though outright depletion of leukocytes enhances susceptibility to infection and neoplasia.
We describe here a class of antiinflammatory agents, N-(fluorenyl-9-methoxycarbonyl) amino acids, which possess activity in a broad range of animal models of inflammation. The activities of these agents are consistent with their ability to block recruitment ofT lymphocytes and neutrophils into inflammatory lesions. However Adjuvant arthritis was elicited in Lewis rats by injecting 0.5 ml of Mycobacterium tuberculosum (1 mg/ml) in pristane into the base of the tail (7). Disease activity was assessed by determining the plasma level of fibrinogen (8) or by plethysmographic evidence of paw edema. Antigen arthritis was induced in New Zealand White rabbits by using ovalbumin as antigen (9) . Disease severity was assessed by measuringjoint width (pm to 0.2 mm), surface temperature (paddle thermistor to 0.10C), and by quantitating plasma fibrinogen. The proliferative response in vitro to antigen challenge of T lymphocytes from the animals was also assessed (10) . The reverse passive Arthus reaction was elicited in SpragueDawley rats as described (11) using human albumin and antialbumin.
Cellular Assays. A two-way mixed lymphocyte reaction (12) was performed using splenocytes from BALB/c and C3H/HEN (Harlan) mice. Oxygen radical-dependent neutrophil chemiluminescence was performed using a Chronolog instrument and luminol to enhance the signal (13 ArWhidonic Acid-and Oxazokoe-Induced Dermatiis. Formation of edema fluid makes the mouse ear measurably thicker. Several of the N-(fluoroenyl-9-methoxycarbonyl) amino acids ( Fig. 1) , when administered i.p., inhibited the infammatory response to topical arachidonic acid (Table 1) . Because arachidonic acid-induced edema is partly mediated by prostaglandins and leukotrienes (5), the ability of several of the compounds to
inhibit the enzymes in the synthetic pathways to these lipids was assessed. NPC 14692 did not inhibit fatty acid cyclooxygenase or 5-lipoxygenase at concentrations to 300 pAM. NPC 15199 and NPC 15669 were without effect on cyclooxygenase at concentrations to 300 pM but were very weak inhibitors of 5-lipoxygenase, with IC50 values of 173 AuM and 69 pM, respectively.
Oxazolone also induces ear edema when administered topically to sensitized animals, largely by a type IV hypersensitivity reaction. Several of the N-(fluorenyl-9-methoxy- N-(Fluorenyl-9-Methoxycarbonyl) Amino Acids Inhibit the Reversed Passive Arthus Reaction, Neutrophil Accumulation at Inflammatory Sites, and the Acute-Phase Response. The reverse passive Arthus reaction is initiated by the formation of antigen-antibody complexes in the skin followed by complement activation and recruitment of neutrophils, leading to capillary damage and leak. In this inflammatory reaction, arachidonic acid metabolites are not important (11) . After i.p. administration, several of the N-(fluorenyl-9-methoxycarbonyl) amino acids inhibited the reaction (Table 1) .
Neutrophils recruited to the inflammatory site play a major role in the edema response to arachidonic acid. Because N-(fluorenyl-9-methoxycarbonyl) amino acids had no effect on cyclooxygenase and little on lipoxygenase, we examined their effects on neutrophil accumulation. Ears that had been fixed with paraformaldehyde 60 min after arachidonic acid administration were examined histologically. Several of the agents were found to dose-dependently inhibit recruitment of neutrophils ( Table 2 , Fig. 2 ). The N-(fluorenyl-9-methoxycarbonyl) amino acids also blocked neutrophil and lymphocyte accumulation in response to oxazolone with similar rank order of potency (data not shown).
Because NPC 15199 and related analogs blocked neutrophil recruitment, we examined their effects on several other neutrophil functions. Platelet-activating factor or phorbol 12-myristate 13- However, it augmented the effects of platelet-activating factor or phorbol ester (Fig. 3) . Phagocytic activity was assessed using RAW264.7 macrophages. NPC 15199 did not block phagocytic activity at concentrations from 1 pM to 100 puM.
An early acute-phase protein response is initiated after adjuvant injection, followed several days later by inflammation ofjoints (7) . Plasma fibrinogen, an acute-phase protein, was measured after adjuvant administration, and the effects of several N-(fluorenyl-9-methoxycarbonyl) amino acids were assessed. In the experiment, animals were treated with drug for 3 consecutive days, beginning at the same time as the injection with adjuvant. Blood was sampled 1 day after the last administration of drug. The N-(fluorenyl-9-methoxycarbonyl) amino acids inhibited adjuvant arthritis (Table 2) . In other experiments, NPC 15199 was evaluated in therapeutic protocols. In these experiments the disease was initiated, and then NPC 15199 was administered on days 7, 8, and 9. When blood was sampled on day 10, NPC 15199 reduced plasma fibrinogen toward control with an IC50 of 10 mg/ml (Fig. 4 rocyte sedimentation rate (17) . Peripheral lymphocytes from these animals exhibit a proliferative response in vitro to the antigen (10). We administered NPC 15199 i.p. before intraarticular antigen. NPC 15199 reduced joint swelling and temperature, as well as erythrocyte sedimentation rate and the circulating level of the acute-phase protein, fibrinogen (Fig. 5) . The proliferative response of peripheral lymphocytes to antigen was also reduced in NPC 15199-treated animals. The stimulation index to ovalbumin was 0.3 + 0.2, 4.8 ± 0.6, and 2.4 ± 0.1 (P < 0.05 compared with 4.8) in cells from nonsensitized controls, sensitized animals, and sensitized animals treated with NPC 15199, respectively. N-(Fluorenyl-9-Methoxycarbonyl) Amino Acids Inhibit the Mixed Lymphocyte Reaction. Because several of the animal models described above, in particular oxazolone edema, adjuvant arthritis, and antigen arthritis, depend on activated T cells, we tested the effects of N-(fluorenyl-9-methoxycarbonyl) amino acids on the mixed lymphocyte reaction. Several of the agents potently inhibited the mixed lymphocyte reaction ( Table 2) .
N-(Fluorenyl-9-Methoxycarbonyl) Amino Acids Do Not Alter Circulating Glucocorticoids or Peripheral Blood Counts. Because glucocorticosteroids have profound antiinflammatory effects we assessed the effects of the N-(fluorenyl-9-methoxycarbonyl) amino acids on circulating levels of an endogenous glucocorticosteroid, corticosterone. Because the circulating concentration of corticosterone varies with a circadian rhythm, all animals were treated simultaneously, and all blood samples were collected within a 15-min period at 11 a.m. In control mice, plasma corticosterone was 131 + 22 ng/ml (n = 6). NPC 15199 was administered i.p. 2 hr before sampling blood. Plasma corticosterone was 93 ± 25 ng/ml after NPC 15199 at 10 mg/kg and was 134 ± 22 ng/ml after the drug at 100 mg/kg. Similarly, after NPC 15669 at 10 mg/kg, corticosterone was 105 ± 18 ng/ml, and after NPC 15199 at 100 mg/kg, corticosterone was 135 ± 28 ng/ml. Because N-(fluorenyl-9-methoxycarbonyl) amino acids blocked neutrophil infiltration into inflammatory sites in vivo while not inhibiting several neutrophil functions in vitro, the (11) . Glucocorticoids are not effective at subtoxic doses in arachidonic acid edema or reversed passive Arthus reaction. The leumedins were effective in all these models. The leumedins may also be distinguished from the cytotoxic agents; in toxicologic studies conducted thus far, leumedins fail to elicit specific end-organ toxicity or alter peripheral or bone marrow cell counts (data not shown). Other antiinflammatory drugs containing fluorene ring structures have been reported-e.g., paranyline, which has been used in the therapy of rheumatoid arthritis and osteoarthritis (18) . The mechanism of action of paranyline is unknown and, aside from the fluorene moiety, its structure is dissimilar from the present compounds, making it unlikely that the two classes of compounds have similar mechanisms.
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